Int. J. Mol. Sci. 2013, 14(4), 7742-7756; doi:10.3390/ijms14047742
Review

Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer

1 Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Research Centre for Reproductive Health, Robinson Institute, University of Adelaide, Adelaide 5005, Australia 2 Genetics and Molecular Pathology, SA Pathology, Women's and Children's Hospital, Adelaide 5006, Australia 3 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide 5000, Australia
* Author to whom correspondence should be addressed.
Received: 1 February 2013; in revised form: 6 March 2013 / Accepted: 7 March 2013 / Published: 10 April 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
PDF Full-text Download PDF Full-Text [193 KB, uploaded 10 April 2013 09:52 CEST]
Abstract: Ovarian cancer remains the most lethal gynaecological cancer. A better understanding of the molecular pathogenesis of ovarian cancer is of critical importance to develop early detection tests and identify new therapeutic targets that would increase survival. Cancer cells depend on de novo lipid synthesis for the generation of fatty acids to meet the energy requirements for increased tumour growth. There is increasing evidence that lipid metabolism is deregulated in cancers, including ovarian cancer. The increased expression and activity of lipogenic enzymes is largely responsible for increased lipid synthesis, which is regulated by metabolic and oncogenic signalling pathways. This article reviews the latest knowledge on lipid metabolism and the alterations in the expression of lipogenic enzymes and downstream signalling pathways in ovarian cancer. Current developments for exploiting lipids as biomarkers for the detection of early stage ovarian cancer and therapeutic targets are discussed. Current research targeting lipogenic enzymes and lipids to increase the cytotoxicity of chemotherapy drugs is also highlighted.
Keywords: ovarian cancer; lipid synthesis; signalling pathways; biomarkers; therapeutic targets

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Pyragius, C.E.; Fuller, M.; Ricciardelli, C.; Oehler, M.K. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 7742-7756.

AMA Style

Pyragius CE, Fuller M, Ricciardelli C, Oehler MK. Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(4):7742-7756.

Chicago/Turabian Style

Pyragius, Carmen E.; Fuller, Maria; Ricciardelli, Carmela; Oehler, Martin K. 2013. "Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer." Int. J. Mol. Sci. 14, no. 4: 7742-7756.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert